Rhythm Pharmaceuticals Inc

RYTM

103.610USD

-0.260-0.25%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Rhythm Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

35 / 159

Overall Ranking

100 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Rhythm Pharmaceuticals Inc Highlights

StrengthsRisks

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 450.49% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 130.13M.

Undervalued

The company’s latest PE is -33.44, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 74.57M shares, decreasing 0.44% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 4.86K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.07.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

139.467

Target Price

+34.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Rhythm Pharmaceuticals Inc is 8.02, ranking 89 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 51.30M, representing a year-over-year increase of 54.28%, while its net profit experienced a year-over-year increase of 20.70%.

Score

Industry at a Glance

Previous score

8.02

Change

0



Financials

5.58

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.57

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.51

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Rhythm Pharmaceuticals Inc is 7.20, ranking 91 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -33.44, which is -85.56% below the recent high of -4.83 and -13.52% above the recent low of -37.96.

Score

Industry at a Glance

Previous score

7.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 35/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Rhythm Pharmaceuticals Inc is 8.67, ranking 13 out of 159 in the Pharmaceuticals industry. The average price target is 127.00, with a high of 141.00 and a low of 110.00.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Rhythm Pharmaceuticals Inc is 7.40, ranking 59 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 112.84 and the support level at 95.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.48

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Rhythm Pharmaceuticals Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 111.74%, representing a quarter-over-quarter increase of 6.13%. The largest institutional shareholder is The Vanguard, holding a total of 6.20M shares, representing 9.29% of shares outstanding, with 72.02% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

4.98M

+39.26%

RA Capital Management, LP

5.68M

+2.16%

Baker Bros. Advisors LP

5.60M

--

PRIMECAP Management Company

Star Investors

4.26M

-12.61%

BlackRock Institutional Trust Company, N.A.

3.93M

+0.55%

New Enterprise Associates (NEA)

2.91M

--

Perceptive Advisors LLC

2.44M

+0.85%

Fidelity Management & Research Company LLC

2.10M

+10.21%

State Street Investment Management (US)

2.03M

+6.35%

Goldman Sachs & Company, Inc.

1.67M

+4.14%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Rhythm Pharmaceuticals Inc is 6.18, ranking 59 out of 159 in the Pharmaceuticals industry. The company's beta value is 2.04. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Rhythm Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Rhythm Pharmaceuticals Inc

RYTM

7.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment